vimarsana.com

Latest Breaking News On - Petra kienle - Page 1 : vimarsana.com

Boehringer Ingelheim: CHMP recommends conditional marketing authorization for Spesolimab as first in class treatment option for generalized pustular psoriasis flares

CHMP positive opinion is based on evidence from the EFFISAYIL 1 trial, the largest clinical trial in patients with generalized pustular psoriasis (GPP) flares1 GPP is a rare and potentially

France generalPetra kienleCarinne brouillonGlobal consensus delphi panelCorporate communicationsBoehringer ingelheimEuropean medicine agencyMedicinal productsHuman useSaint louis university hospitalManaging directorsHuman pharma

U S FDA approves first treatment option for generalized pustular psoriasis flares in adults

Press release content from Business Wire. The AP news staff was not involved in its creation.

New yorkUnited statesRheinland pfalzPetra kienleCarinne brouillonMark lebwohlEricj waldman department of dermatologyIcahn school of medicine at mount sinaiCorporate communicationsDrug administrationEuropean medicines agencyBoehringer ingelheimClinical therapeuticsIcahn schoolMount sinaiManaging directors

Boehringer Ingelheim: U S FDA approves first treatment option for generalized pustular psoriasis flares in adults

Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares After

New yorkUnited statesPetra kienleCarinne brouillonMark lebwohlEricj waldman department of dermatologyIcahn school of medicine at mount sinaiCorporate communicationsEuropean medicines agencyBoehringer ingelheimDrug administrationClinical therapeuticsIcahn schoolMount sinaiManaging directorsHuman pharma

vimarsana © 2020. All Rights Reserved.